• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Neupath Health Announces Strategic Acquisition of Virtual Care Business and Management Changes

Share:

June 15, 2021

NeuPath Health Inc. (TSXV: NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics that deliver category-leading treatment for chronic pain, as well as spinal injuries, sports-related injuries, and concussions, today announced a strategic transaction to acquire KumoCare, a virtual care platform to further expand NeuPath’s virtual care and telemedicine offerings. Prior to the pandemic, patients and their physicians alike preferred an in-person care experience. The care model changed out of necessity in 2020 to bring about virtual care via telemedicine that was both clinically useful and economically viable. NeuPath went from no virtual care visits in 2019 to nearly 10% of all consultations in 2020 and is currently above those levels in 2021. There are numerous benefits to NeuPath from this transaction, including:

  • reduced wait times with more efficient and easy access for patients and their physicians alike;
  • drives a new revenue line for NeuPath across all of NeuPath’s offerings;
  • the ability to provide care beyond the physical constraints of clinic locations and hours;
  • seamless integration with health card validation and payment processing; and
  • NeuPath intends to unveil additional business lines over time, powered by the KumoCare platform.

“The acquisition of KumoCare and its telemedicine platform is an important step forward in the advancement of our virtual care strategy which will allow us to elevate the patient care experience and unlock additional revenue-generating opportunities in both the public and private healthcare segments,” stated Grant Connelly, CEO of NeuPath. Mr. Connelly further commented, “NeuPath’s goal is to be able to deliver the best quality care, as quickly and efficiently as possible, and wherever possible, while improving outcomes. This transaction enables us to achieve those goals by providing the best tools and a complete service offering to our patients and the physicians who deliver that care. We encourage you to explore KumoCare’s offering on their website (www.kumocare.com) and their app is available on both the AppStore for iOS devices and Google Play for Android devices.”

Under the terms of the definitive agreement and in consideration for the purchase of 100% of the issued and outstanding shares of Aidly Inc. and KumoCare Peel York Inc., the owners of KumoCare, NeuPath has agreed to pay total consideration of up to $1.5 million subject to a net working capital adjustment, payable as follows: (i) $1.0 million payable in NeuPath shares based on the volume-weighted average price for the ten consecutive trading days immediately preceding the closing date; and (ii) additional cash consideration of up to $0.5 million, based on the achievement of certain operational targets. The acquisition is subject to customary closing conditions, including approval by the TSX Venture Exchange. The transaction is expected to close in the third quarter of 2021.

Management Changes

As part of the KumoCare acquisition, Ben Fagan has agreed to join NeuPath as Chief Technology Officer. Prior to joining KumoCare as Chief Technology Officer, Mr. Fagan spent ten years in the financial sector, designing and managing the development of complex capital markets software for TD Securities and BMO Capital Markets. Mr. Fagan obtained a Master’s of Financial Engineering from the University of Michigan.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

In addition, NeuPath announces that Stephen Lemieux, Chief Financial Officer, will resign effective June 30, 2021, to pursue a new career opportunity. NeuPath has initiated a search for a replacement and has appointed Jeff Zygouras as the interim Chief Financial Officer until such time as NeuPath finds a permanent replacement for Mr. Lemieux. Mr. Zygouras, CPA, CA is a highly experienced financial professional who has served as NeuPath’s Controller since 2019. Prior to joining NeuPath, Mr. Zygouras held senior financial roles at Nuvo Pharmaceuticals Inc. and Crescita Therapeutics Inc. and was an auditor at EY Canada.

“We are highly confident in Jeff’s ability to take on this role, given his extensive experience and deep knowledge of the business. NeuPath has benefited tremendously from Stephen’s passion for our mission combined with the financial oversight he has provided in his role as CFO,” stated Dianne Carmichael, Chair of NeuPath’s Board of Directors. “Stephen was integral in building NeuPath’s current financial systems and processes, NeuPath’s go public transaction, and NeuPath’s success to date. We appreciate his commitment and work and wish him well in his new opportunity.”

Source: Biospace

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Revive Therapeutics Acquires Unique Psilocybin AssetsRevive Therapeutics Acquires Unique Psilocybin Assets
  • Celgene Wins Approval for Drug key to Bristol BuyoutCelgene Wins Approval for Drug key to Bristol Buyout
  • Catalent to Buy Paragon Bioservices for $1.2 BillionCatalent to Buy Paragon Bioservices for $1.2 Billion
  • Full Results of EndeavorRX Adjunct Trial Show Longer Benefits with or Without Stimulant TherapyFull Results of EndeavorRX Adjunct Trial Show Longer Benefits with or Without Stimulant Therapy
  • Smart Bed Maker Sleep Number Adds New Features to Monitor HealthSmart Bed Maker Sleep Number Adds New Features to Monitor Health
  • GRAIL, Carrum Health Partners to Help Employers Address Cancer CareGRAIL, Carrum Health Partners to Help Employers Address Cancer Care
  • 2020 Insights into the Cancer Vaccines Market – Pipeline Analysis Report – ResearchAndMarkets.com2020 Insights into the Cancer Vaccines Market – Pipeline Analysis Report – ResearchAndMarkets.com
  • Regeneron Completes Purchase of Sanofi’s Stake in Libtayo® (cemiplimab)Regeneron Completes Purchase of Sanofi’s Stake in Libtayo® (cemiplimab)

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications